{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:45:03Z","timestamp":1792622703385,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current treatments of polymyositis and dermatomyositis (PM\/DM) depend on non-specific immunosuppressants. This study was performed to elucidate the role of interleukin (IL)-23, as their possible therapeutic target. As was reported earlier in PM\/DM patients, serum IL-23 levels were elevated in mice with C protein induced-myositis (CIM), a murine model of PM. IL-23 was expressed by macrophages in the PM\/DM and CIM muscles and by dendritic cells and macrophages in the lymph nodes from the CIM mice. It was also expressed by macrophages in the chemically injured muscles, but not those recruited into the muscles by footpad injection of Freund\u2019s complete adjuvant, demonstrating that IL-23 production should be associated with muscle damage. Genetic deletion of IL-23 as well as preventive and therapeutic administration of blocking antibodies against IL-23p19 subunit suppressed CIM. When lymph node cells from the CIM mice were transferred adoptively into naive wild type or IL-23p19 deficient recipient mice, both recipients developed myositis equally. Thus, elevated IL-23 should promote dendritic cells and macrophages to activate the autoaggressive T cells. Our findings suggest that IL-23 should mediate positive feedback loop from the muscle damage to the T cell activation and be a promising therapeutic target for autoimmune myositis.<\/jats:p>","DOI":"10.1038\/s41598-018-23539-4","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T01:47:57Z","timestamp":1522288077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Interleukin-23 as a therapeutic target for inflammatory myopathy"],"prefix":"10.1038","volume":"8","author":[{"given":"Natsuka","family":"Umezawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimito","family":"Kawahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Yoshihashi-Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"23539_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3109\/14397595.2015.1091137","volume":"26","author":"H Tomimitsu","year":"2016","unstructured":"Tomimitsu, H. et al. Epidemiologic analysis of the clinical features of Japanese patients with polymyositis and dermatomyositis. Mod. Rheumatol. 26, 398\u2013402 (2016).","journal-title":"Mod. Rheumatol."},{"key":"23539_CR2","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.4049\/jimmunol.167.7.4051","volume":"167","author":"J Nishio","year":"2001","unstructured":"Nishio, J., Suzuki, M., Miyasaka, N. & Kohsaka, H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J. Immunol. 167, 4051\u20134058 (2001).","journal-title":"J. Immunol."},{"key":"23539_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ana.20293","volume":"56","author":"O Benveniste","year":"2004","unstructured":"Benveniste, O. et al. Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann. Neurol. 56, 867\u2013872 (2004).","journal-title":"Ann. Neurol."},{"key":"23539_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/art.22521","volume":"56","author":"T Sugihara","year":"2007","unstructured":"Sugihara, T. et al. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum. 56, 1304\u20131314 (2007).","journal-title":"Arthritis Rheum."},{"key":"23539_CR5","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1002\/art.27625","volume":"62","author":"T Sugihara","year":"2010","unstructured":"Sugihara, T. et al. Definitive engagement of cytotoxic CD8 T cells in C protein-induced myositis, a murine model of polymyositis. Arthritis Rheum. 62, 3088\u20133092 (2010).","journal-title":"Arthritis Rheum."},{"key":"23539_CR6","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1002\/art.34629","volume":"64","author":"N Okiyama","year":"2012","unstructured":"Okiyama, N. et al. T lymphocytes and muscle condition act like seeds and soil in a murine polymyositis model. Arthritis Rheum. 64, 3741\u20133749 (2012).","journal-title":"Arthritis Rheum."},{"key":"23539_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/art.39017","volume":"67","author":"N Kimura","year":"2015","unstructured":"Kimura, N., Hirata, S., Miyasaka, N., Kawahata, K. & Kohsaka, H. Injury and subsequent regeneration of muscles for activation of local innate immunity to facilitate the development and relapse of autoimmune myositis in C57BL\/6 mice. Arthritis Rheumatol. 67, 1107\u20131116 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"23539_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/BOR.0000000000000109","volume":"26","author":"IE Lundberg","year":"2014","unstructured":"Lundberg, I. E., Vencovsky, J. & Alexanderson, H. Therapy of myositis: biological and physical. Curr. Opin. Rheumatol. 26, 704\u2013711 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"23539_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/03009742.2010.517215","volume":"40","author":"H Shen","year":"2011","unstructured":"Shen, H., Xia, L., Lu, J. & Xiao, W. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand. J. Rheumatol. 40, 217\u2013220 (2011).","journal-title":"Scand. J. Rheumatol."},{"key":"23539_CR10","first-page":"345347","volume":"2013","author":"X Tang","year":"2013","unstructured":"Tang, X. et al. Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin. Dev. Immunol. 2013, 345347 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"23539_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/art.33350","volume":"64","author":"A Tournadre","year":"2012","unstructured":"Tournadre, A., Lenief, V., Eljaafari, A. & Miossec, P. Immature muscle precursors are a source of interferon-beta in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum. 64, 533\u2013541 (2012).","journal-title":"Arthritis Rheum."},{"key":"23539_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","volume":"13","author":"B Oppmann","year":"2000","unstructured":"Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715\u2013725 (2000).","journal-title":"Immunity"},{"key":"23539_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888\u2013898 (2009).","journal-title":"N. Engl. J. Med."},{"key":"23539_CR14","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","volume":"168","author":"C Parham","year":"2002","unstructured":"Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699\u20135708 (2002).","journal-title":"J. Immunol."},{"key":"23539_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","volume":"202","author":"CL Langrish","year":"2004","unstructured":"Langrish, C. L. et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96\u2013105 (2004).","journal-title":"Immunol. Rev."},{"key":"23539_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.micinf.2004.02.012","volume":"6","author":"KR Bastos","year":"2004","unstructured":"Bastos, K. R. et al. What kind of message does IL-12\/IL-23 bring to macrophages and dendritic cells? Microbes Infect. 6, 630\u2013636 (2004).","journal-title":"Microbes Infect."},{"key":"23539_CR17","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/art.24689","volume":"60","author":"N Okiyama","year":"2009","unstructured":"Okiyama, N. et al. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 60, 2505\u20132512 (2009).","journal-title":"Arthritis Rheum."},{"key":"23539_CR18","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.4049\/jimmunol.168.11.5448","volume":"168","author":"ML Belladonna","year":"2002","unstructured":"Belladonna, M. L. et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168, 5448\u20135454 (2002).","journal-title":"J. Immunol."},{"key":"23539_CR19","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.4049\/jimmunol.163.6.3100","volume":"163","author":"U Grohmann","year":"1999","unstructured":"Grohmann, U. et al. IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo. J. Immunol. 163, 3100\u20133105 (1999).","journal-title":"J. Immunol."},{"key":"23539_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nri2800","volume":"10","author":"DJ Cua","year":"2010","unstructured":"Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10, 479\u2013489 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"23539_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.biocel.2008.04.027","volume":"41","author":"ZY Tan","year":"2009","unstructured":"Tan, Z. Y., Bealgey, K. W., Fang, Y., Gong, Y. M. & Bao, S. Interleukin-23: immunological roles and clinical implications. Int. J. Biochem. Cell Biol. 41, 733\u2013735 (2009).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"23539_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng, M. W. et al. IL-12 and IL-23cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719\u2013729 (2015).","journal-title":"Nat. Med."},{"key":"23539_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/j.gastro.2016.10.018","volume":"152","author":"C Abraham","year":"2017","unstructured":"Abraham, C., Dulai, P. S., Vermeire, S. & Sandborn, W. J. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology 152, 374\u2013388 (2017).","journal-title":"Gastroenterology"},{"key":"23539_CR24","first-page":"2269","volume":"118","author":"N Kamada","year":"2008","unstructured":"Kamada, N. et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23\/IFN-gamma axis. J. Clin. Invest. 118, 2269\u20132280 (2008).","journal-title":"J. Clin. Invest."},{"key":"23539_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1084\/jem.20030896","volume":"198","author":"CA Murphy","year":"2003","unstructured":"Murphy, C. A. et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951\u20131957 (2003).","journal-title":"J. Exp. Med."},{"key":"23539_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","volume":"34","author":"Y Iwakura","year":"2011","unstructured":"Iwakura, Y., Ishigame, H., Saijo, S. & Nakae, S. Functional specialization of interleukin-17 family members. Immunity 34, 149\u2013162 (2011).","journal-title":"Immunity"},{"key":"23539_CR27","first-page":"61","volume":"119","author":"S Haak","year":"2009","unstructured":"Haak, S. et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 119, 61\u201369 (2009).","journal-title":"J. Clin. Invest."},{"key":"23539_CR28","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/eji.201242598","volume":"42","author":"AL Croxford","year":"2012","unstructured":"Croxford, A. L., Mair, F. & Becher, B. IL-23: one cytokine in control of autoimmunity. Eur. J. Immunol. 42, 2263\u20132273 (2012).","journal-title":"Eur. J. Immunol."},{"key":"23539_CR29","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.4049\/jimmunol.179.12.8098","volume":"179","author":"K Kreymborg","year":"2007","unstructured":"Kreymborg, K. et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J. Immunol. 179, 8098\u20138104 (2007).","journal-title":"J. Immunol."},{"key":"23539_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature04808","volume":"442","author":"JL Langowski","year":"2006","unstructured":"Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461\u2013465 (2006).","journal-title":"Nature"},{"key":"23539_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4049\/jimmunol.171.2.600","volume":"171","author":"CH Lo","year":"2003","unstructured":"Lo, C. H. et al. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171, 600\u2013607 (2003).","journal-title":"J. Immunol."},{"key":"23539_CR32","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.18632\/oncotarget.2069","volume":"5","author":"M Helbling","year":"2014","unstructured":"Helbling, M. et al. Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. Oncotarget 5, 4671\u20134682 (2014).","journal-title":"Oncotarget"},{"key":"23539_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1203475416665601","volume":"21","author":"JK Qiang","year":"2017","unstructured":"Qiang, J. K., Kim, W. B., Baibergenova, A. & Alhusayen, R. Risk of Malignancy in Dermatomyositis and Polymyositis: A Systematic Review and Meta-Analysis. J. Cutan. Med. Surg. 21, 131\u2013136 (2017).","journal-title":"J. Cutan. Med. Surg."},{"key":"23539_CR34","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/art.38630","volume":"66","author":"K Oishi","year":"2014","unstructured":"Oishi, K. et al. A crucial role of L-selectin in C protein-induced experimental polymyositis in mice. Arthritis Rheumatol. 66, 1864\u20131871 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"23539_CR35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon, K. B. et al. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N. Engl. J. Med. 373, 136\u2013144 (2015).","journal-title":"N. Engl. J. Med."},{"key":"23539_CR36","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp, K. et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br. J. Dermatol. 173, 930\u2013939 (2015).","journal-title":"Br. J. Dermatol."},{"key":"23539_CR37","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature01355","volume":"421","author":"DJ Cua","year":"2003","unstructured":"Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744\u2013748 (2003).","journal-title":"Nature"},{"key":"23539_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"23539_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ni.1698","volume":"10","author":"MJ McGeachy","year":"2009","unstructured":"McGeachy, M. J. et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10, 314\u2013324 (2009).","journal-title":"Nat. Immunol ."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23539-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T20:54:17Z","timestamp":1693601657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23539-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23539"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23539-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"4 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K. has received consulting fees and\/or speaking fees from Abbott Japan, AbbVie, Astellas Pharma, Eli Lilly and Company, Glaxo Smith Kline, Janssen Pharmaceutical, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan and UCB Japan. N.U., K.K., F.M., N.K., Y.Y.-N. and N.M. declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5498"}}